Dr. Mark Ashton, Evotec's executive vice president, business development, said, "We believe that the quality of future drug candidates is very much dependent on the identification of high quality starting points. To this end we have established a platform of screening technologies that have been proven to identify high-class hit molecules. We are looking forward to working with Biogen Idec and identifying interesting hit compounds for them."
Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference